- Piramal Pharma Solutions has entered a strategic collaboration with Ajinomoto Bio-Pharma Services to support ADC manufacturing using AJICAP technology.
- The partnership includes customer referrals and a planned technology transfer to enable Piramal to manufacture AJICAP-based products.
Piramal Pharma Solutions has announced a strategic collaboration with Ajinomoto Bio-Pharma Services to expand capabilities in antibody-drug conjugate (ADC) development and manufacturing. The agreement establishes a framework for mutual customer referrals and technology integration to support ADC programs across development and commercial stages.
Under the collaboration, Piramal will refer customers seeking ADC manufacturing technology to Ajinomoto’s AJICAP platform, while Ajinomoto will direct customers to Piramal as a CDMO for contract manufacturing of AJICAP-based products. The companies also plan to enter a Material Transfer Agreement to enable the transfer of technology and expertise required for manufacturing.
The collaboration is intended to combine Ajinomoto’s AJICAP site-specific conjugation technology with Piramal’s experience in ADC manufacturing. Piramal stated that the agreement will enhance its ability to support customers with integrated development and manufacturing services, including clinical and commercial production.
Piramal brings more than two decades of experience in ADC development and manufacturing, including over 15 years in commercial-scale production. The company operates a global network of facilities and continues to expand its ADC capacity to meet growing demand.
“With the implementation of these capabilities, we will accelerate innovation and expand access to this technology for our customers and their patients worldwide.”
Peter DeYoung, CEO of Piramal Global Pharma
